IN PERSON: One of modern science's greatest accomplishments has been its ability to design drugs to target specific diseases including tuberculosis, Type II diabetes, and, more recently, COVID-19. The pharmaceutical industry is listed as a $1.7T market, with new drug development estimated to be between $800M to $1.5B. In this course, participants will use research-grade software to explore how new drugs are designed. The course consists of two parts: pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body). In the first part, we'll consider topics such as ADME: absorption, distribution, metabolism, and excretion, along with scoring profiles such as Lipinski's Rule. In the second part, we'll explore target proteins for new drugs, conduct basic bioinformatics studies using tools such as DrugBank, and conduct basic protein-ligand docking to measure binding affinities. Discussion of clinical aspects of drug design will be included as appropriate. | Lecture + Q&A, Active Skill Learning.
Max enrollment: 15.
Location: Judea Reform Congregation, 1933 W. Cornwallis Rd, Durham NC 27705
